Not blinding sampling times [Bioanalytics]

posted by Obinoscopy  – USA, 2018-08-20 00:20 (2470 d 10:35 ago) – Posting: # 19177
Views: 4,565

Hi Helmut,

❝ Even if substantial carry-over is not apparent in method validation (which would call for injecting mobile phase between samples), it exists. The EMA’s GL tells us [...]



Going by that guideline, will it be safe to say that the converse it also true. That is:

If it appears there is no carry-over, study samples should be randomised


Well, just as you said, carryover is always very likely. Thus complete randomisation will not be the reasonable path to follow.

Thanks guys, at least I am glad I let my thoughts out and not get drowned in them.

Scopy

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
31 visitors (0 registered, 31 guests [including 24 identified bots]).
Forum time: 10:56 CEST (Europe/Vienna)

An expert is someone who knows some of the worst mistakes
that can be made in his subject,
and how to avoid them.    Werner Heisenberg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5